IRADIMED CORP (IRMD)
US46266A1097 - Common Stock
Taking everything into account, IRMD scores 7 out of 10 in our fundamental rating. IRMD was compared to 192 industry peers in the Health Care Equipment & Supplies industry. IRMD gets an excellent profitability rating and is at the same time showing great financial health properties. IRMD is growing strongly while it is still valued neutral. This is a good combination! These ratings could make IRMD a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year IRMD was profitable.
In the past year IRMD had a positive cash flow from operations.
Each year in the past 5 years IRMD has been profitable.
Each year in the past 5 years IRMD had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 18.66%, IRMD belongs to the best of the industry, outperforming 97.92% of the companies in the same industry.
The Return On Equity of IRMD (24.08%) is better than 96.35% of its industry peers.
IRMD has a better Return On Invested Capital (20.93%) than 97.92% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IRMD is significantly above the industry average of 8.50%.
The 3 year average ROIC (15.74%) for IRMD is below the current ROIC(20.93%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.66% | ||
| ROE | 24.08% | ||
| ROIC | 20.93% |
ROA(3y)14.97%
ROA(5y)12.26%
ROE(3y)18.14%
ROE(5y)14.8%
ROIC(3y)15.74%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 26.23%, IRMD belongs to the top of the industry, outperforming 97.40% of the companies in the same industry.
IRMD's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 30.57%, IRMD belongs to the top of the industry, outperforming 97.92% of the companies in the same industry.
In the last couple of years the Operating Margin of IRMD has grown nicely.
IRMD has a better Gross Margin (76.51%) than 88.02% of its industry peers.
IRMD's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.57% | ||
| PM (TTM) | 26.23% | ||
| GM | 76.51% |
OM growth 3YN/A
OM growth 5Y9.17%
PM growth 3Y82.43%
PM growth 5Y4.85%
GM growth 3Y0.98%
GM growth 5Y0.05%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IRMD is creating value.
The number of shares outstanding for IRMD has been increased compared to 1 year ago.
IRMD has more shares outstanding than it did 5 years ago.
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 18.20 indicates that IRMD is not in any danger for bankruptcy at the moment.
IRMD's Altman-Z score of 18.20 is amongst the best of the industry. IRMD outperforms 93.23% of its industry peers.
IRMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 18.2 |
ROIC/WACC2.08
WACC10.08%
2.3 Liquidity
IRMD has a Current Ratio of 4.65. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.65, IRMD is in the better half of the industry, outperforming 65.10% of the companies in the same industry.
A Quick Ratio of 3.87 indicates that IRMD has no problem at all paying its short term obligations.
IRMD has a Quick ratio of 3.87. This is in the better half of the industry: IRMD outperforms 68.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.65 | ||
| Quick Ratio | 3.87 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 35.78% over the past year.
IRMD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 22.34% yearly.
The Revenue has grown by 23.01% in the past year. This is a very strong growth!
IRMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.58% yearly.
EPS 1Y (TTM)35.78%
EPS 3Y53.4%
EPS 5Y22.34%
EPS growth Q2Q21.88%
Revenue 1Y (TTM)23.01%
Revenue growth 3Y27.38%
Revenue growth 5Y16.58%
Revenue growth Q2Q17.44%
3.2 Future
IRMD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.28% yearly.
The Revenue is expected to grow by 10.64% on average over the next years. This is quite good.
EPS Next Y5.45%
EPS Next 2Y7.28%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.27%
Revenue Next 2Y10.64%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 28.28, IRMD can be considered very expensive at the moment.
IRMD's Price/Earnings ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 78.65% of the companies in the same industry.
IRMD's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.84.
With a Price/Forward Earnings ratio of 26.82, IRMD can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, IRMD is valued a bit cheaper than the industry average as 78.13% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of IRMD to the average of the S&P500 Index (21.35), we can say IRMD is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.28 | ||
| Fwd PE | 26.82 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 77.08% of the companies listed in the same industry.
IRMD's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 71.88% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 97.1 | ||
| EV/EBITDA | 23.08 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IRMD does not grow enough to justify the current Price/Earnings ratio.
IRMD has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)5.19
PEG (5Y)1.27
EPS Next 2Y7.28%
EPS Next 3YN/A
5. Dividend
5.1 Amount
IRMD has a Yearly Dividend Yield of 1.45%. Purely for dividend investing, there may be better candidates out there.
IRMD's Dividend Yield is rather good when compared to the industry average which is at 1.69. IRMD pays more dividend than 95.31% of the companies in the same industry.
IRMD's Dividend Yield is slightly below the S&P500 average, which is at 2.41.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.45% |
5.2 History
IRMD does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
76.88% of the earnings are spent on dividend by IRMD. This is not a sustainable payout ratio.
DP76.88%
EPS Next 2Y7.28%
EPS Next 3YN/A
IRADIMED CORP
NASDAQ:IRMD (4/26/2024, 7:00:02 PM)
After market: 41.86 0 (0%)41.86
+0.39 (+0.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap529.95M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.45% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 28.28 | ||
| Fwd PE | 26.82 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)5.19
PEG (5Y)1.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.66% | ||
| ROE | 24.08% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 30.57% | ||
| PM (TTM) | 26.23% | ||
| GM | 76.51% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.65 | ||
| Quick Ratio | 3.87 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)35.78%
EPS 3Y53.4%
EPS 5Y
EPS growth Q2Q
EPS Next Y5.45%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)23.01%
Revenue growth 3Y27.38%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y